Aldeyra Therapeutics Inc ALDX.OQ ALDX.O is expected to show no change in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Aldeyra Therapeutics Inc is for a loss of 24 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Aldeyra Therapeutics Inc is $9.50, about 46.6% above its last closing price of $5.07
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.23 | -0.24 | -0.16 | Beat | 34.2 |
Mar. 31 2025 | -0.30 | -0.28 | -0.17 | Beat | 39.3 |
Dec. 31 2024 | -0.26 | -0.23 | -0.27 | Missed | -19.9 |
Sep. 30 2024 | -0.26 | -0.25 | -0.25 | Met | -1.2 |
Jun. 30 2024 | -0.14 | -0.14 | -0.28 | Missed | -97.5 |
Mar. 31 2024 | -0.10 | -0.11 | -0.14 | Missed | -26.5 |
Dec. 31 2023 | -0.05 | -0.14 | -0.08 | Beat | 43 |
Sep. 30 2023 | -0.22 | -0.24 | -0.14 | Beat | 41.3 |
This summary was machine generated November 3 at 21:55 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)